Header Logo

Connection

Lynn Morris to Animals

Back to Details
This is a "connection" page, showing publications Lynn Morris has written about Animals.
Lynn Morris
Connection Strength
0,976
Animals
  1. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022 09; 28(9):1924-1932.
    View in: PubMed
    Score: 0,162
  2. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev. 2017 01; 275(1):217-229.
    View in: PubMed
    Score: 0,110
  3. Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS. 2009 Sep; 4(5):358-63.
    View in: PubMed
    Score: 0,066
  4. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. BMJ Open. 2023 08 28; 13(8):e076843.
    View in: PubMed
    Score: 0,044
  5. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. J Virol. 2022 05 25; 96(10):e0027022.
    View in: PubMed
    Score: 0,040
  6. Neutralizing antibody responses to HIV-1 infection. IUBMB Life. 2002 Apr-May; 53(4-5):197-9.
    View in: PubMed
    Score: 0,039
  7. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nat Commun. 2022 02 16; 13(1):903.
    View in: PubMed
    Score: 0,039
  8. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. Viruses. 2021 07 02; 13(7).
    View in: PubMed
    Score: 0,038
  9. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
    View in: PubMed
    Score: 0,037
  10. Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. Viruses. 2021 03 02; 13(3).
    View in: PubMed
    Score: 0,037
  11. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. J Virol. 2019 04 15; 93(8).
    View in: PubMed
    Score: 0,032
  12. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to a4ß7. PLoS Pathog. 2018 08; 14(8):e1007278.
    View in: PubMed
    Score: 0,031
  13. Neutralization tiers of HIV-1. Curr Opin HIV AIDS. 2018 03; 13(2):128-136.
    View in: PubMed
    Score: 0,030
  14. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406).
    View in: PubMed
    Score: 0,029
  15. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
    View in: PubMed
    Score: 0,028
  16. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med. 2016 09 28; 8(358):358ra125.
    View in: PubMed
    Score: 0,027
  17. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine. 2016 Oct; 12:196-207.
    View in: PubMed
    Score: 0,027
  18. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54.
    View in: PubMed
    Score: 0,026
  19. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18; 41(6):909-18.
    View in: PubMed
    Score: 0,024
  20. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014 Oct 24; 289(43):29912-26.
    View in: PubMed
    Score: 0,023
  21. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 May 10; 340(6133):751-6.
    View in: PubMed
    Score: 0,021
  22. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009 Aug; 15(8):866-70.
    View in: PubMed
    Score: 0,016
  23. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008 Dec; 82(23):11651-68.
    View in: PubMed
    Score: 0,015
  24. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006 Mar; 80(5):2515-28.
    View in: PubMed
    Score: 0,013
  25. Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. Fertil Steril. 2005 Oct; 84(4):1001-10.
    View in: PubMed
    Score: 0,013
  26. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003 Feb; 19(2):133-44.
    View in: PubMed
    Score: 0,010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.